EMA committee recommends approval of Sanofi & Regeneron’s Dupixent to treat eosinophilic esophagitis in children as young as 1 year old: Paris Monday, September 23, 2024, 11:00 ...

In addition to other MM indications, Isatuximab's anti-CD38 competitor on the US market, daratumumab (Darzalex — Johnson & Johnson), also carries a first-line indication for transplant-ineligible MM ...

AM(IST)on Monday in an upbeat market. Glenmark Pharmaceuticals Ltd.(up 6.99 per cent), Mankind Pharma Ltd.(up 3.47 per cent), ...

The Federal Trade Commission (FTC) has sued the top three pharmacy benefit managers (PBMs) in the US for operating a ...

Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the U.S Food and Drug Administration (FDA) has cleared its investigational new drug (IND) ...

With its Truenat molecular test for infectious vector borne diseases and tuberculosis, Molbio Diagnostics has made testing ...

FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices – Includes Caremark, Express Scripts, ...

Discover why LRLCF is a promising investment opportunity with solid earnings stability, competitive advantages, and sustained ...

The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially ...

The state has further attempted to regulate PBMs since passing Act 900. In May 2022, the state sued the drug manufacturers ...